What is he best known for?
The fields of study he is best known for:
- Gene
- Cancer
- Internal medicine
His primary areas of study are Cell biology, Ezrin, Myotilin, Palladin and Pathology.
The various areas that he examines in his Cell biology study include Transfection and Cytoskeleton.
His Cytoskeleton research incorporates elements of Natural killer cell and Intercellular adhesion molecule.
His work carried out in the field of Ezrin brings together such families of science as Cell adhesion molecule, Actin cytoskeleton and Protein kinase A.
His research in Myotilin intersects with topics in FLNC, Filamin, Genetics and Actinin.
His studies in Pathology integrate themes in fields like Ovarian carcinoma and Ovary.
His most cited work include:
- α‐actinin revisited: A fresh look at an old player (371 citations)
- Association of ezrin with intercellular adhesion molecule-1 and -2 (ICAM-1 and ICAM-2). Regulation by phosphatidylinositol 4, 5-bisphosphate. (298 citations)
- Myotilin is mutated in limb girdle muscular dystrophy 1A (248 citations)
What are the main themes of his work throughout his whole career to date?
Olli Carpén mainly focuses on Cell biology, Cancer research, Internal medicine, Pathology and Cancer.
Olli Carpén combines subjects such as Merlin and Ezrin, Palladin, Actin cytoskeleton, Cytoskeleton with his study of Cell biology.
Olli Carpén has researched Ezrin in several fields, including Cell morphology and Phosphorylation.
The study incorporates disciplines such as Myotilin, Stress fiber and Actin in addition to Palladin.
His studies deal with areas such as Gastroenterology, Endocrinology and Oncology as well as Internal medicine.
The concepts of his Cancer study are interwoven with issues in Carcinoma and Computational biology.
He most often published in these fields:
- Cell biology (31.95%)
- Cancer research (34.19%)
- Internal medicine (36.10%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (36.10%)
- Cancer research (34.19%)
- Cancer (26.52%)
In recent papers he was focusing on the following fields of study:
His main research concerns Internal medicine, Cancer research, Cancer, Ovarian cancer and Oncology.
His Internal medicine research is multidisciplinary, relying on both Gastroenterology and Differential diagnosis.
His Cancer study integrates concerns from other disciplines, such as Carcinoma and Computational biology.
His work deals with themes such as Tissue microarray and Adenocarcinoma, which intersect with Carcinoma.
His Adenocarcinoma research includes elements of Histology and Pathology.
His Oncology research is multidisciplinary, incorporating elements of Clinical trial, Stage, Hazard ratio, Biomarker and Colorectal cancer.
Between 2017 and 2021, his most popular works were:
- Neuropathologic features of four autopsied COVID-19 patients. (42 citations)
- A Functional Homologous Recombination Assay Predicts Primary Chemotherapy Response and Long-Term Survival in Ovarian Cancer Patients. (30 citations)
- A Functional Homologous Recombination Assay Predicts Primary Chemotherapy Response and Long-Term Survival in Ovarian Cancer Patients. (30 citations)
In his most recent research, the most cited papers focused on:
- Gene
- Cancer
- Internal medicine
Olli Carpén mostly deals with Cancer, Ovarian cancer, Internal medicine, Oncology and Cancer research.
Within one scientific family, Olli Carpén focuses on topics pertaining to Carcinoma under Cancer, and may sometimes address concerns connected to Immunohistochemistry, Tissue microarray, Adenocarcinoma, Cell and Lectin.
His biological study spans a wide range of topics, including Histology and Pathology.
His studies in Ovarian cancer integrate themes in fields like Serous fluid and Chemotherapy.
While the research belongs to areas of Oncology, Olli Carpén spends his time largely on the problem of Clinical trial, intersecting his research to questions surrounding Drug resistance, Gynecologic oncology and Combination therapy.
The concepts of his Cancer research study are interwoven with issues in Endometriosis, Antigen, Immunoassay, Breast cancer and PI3K/AKT/mTOR pathway.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
